Restore Bladder Function with NURO

Welcome to an office-based treatment that can restore* bladder function and quality of life for your OAB patients — without the side effects of medications or potential self-catheterization.‡,1

The Medtronic NURO™ system delivers electrical pulses through a needle to stimulate the afferent fibers of the tibial nerve that runs posterior to the medial malleolus and extends to the sacral nerve plexus. This treatment is called Percutaneous Tibial Neuromodulation (PTNM), otherwise known as Percutaneous Tibial Neurostimulation (PTNS).

NURO II device side angle view against white background, with eight sessions and full battery displayed on screen

A Simple, Office-Based Therapy for Overactive Bladder

The NURO system is easy to use and manage in almost any practice setting.

Pay for sessions as you need them

Our pay-as-you-go model allows you to purchase single-use therapy session kits for your NURO device as you need them.


Free your time to see other patients

NURO self-administers for 30 minutes while the patient remains comfortably seated.



NURO is designed for your convenience with 2-day therapy session kit delivery, adjustable stimulation, and the ability to pause and resume a session.

A pair of hands holds the NURO II device

Identify candidates for PTNM

Review diagnosis and treatment guidelines to identify patients who may benefit from PTNM therapy.

Doctor and patient discuss NURO II system

Get started with NURO

You can start treating patients with the NURO System in just 4 easy steps.


Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.

Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.

While the NURO device was not used in the studies cited here, since it delivers equivalent stimulation therapy as the device used in the studies, a user can expect similar performance.


Peters, K. M., S. A. Macdiarmid, et al. (2009). Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 182(3): 1055-1061.